Corvus completes enrollment in dose-selection part of Phase 1/1b study
Corvus Pharmaceuticals announced biomarker findings from its ongoing Phase 1/1b study of CPI-444 as a single agent and in combination with Genentech's TECENTRIQ, a fully humanized monoclonal antibody targeting protein programmed cell death ligand 1. CPI-444 is a selective and potent inhibitor of the adenosine A2A receptor. The data were presented today in a poster session by Ian McCaffery, Ph.D., vice president, Translational Sciences at Corvus, at the European Society for Medical Oncology 2016 Congress at the Bella Center in Copenhagen, Denmark. "The initial part of our Phase 1/1b trial was designed to provide data on optimum dosing, safety and relevant biomarkers, and we have achieved that goal. We have completed enrollment in the dose-selection part of the trial, which enrolled 48 patients in four cohorts. We now have a solid understanding of dose, schedule, pharmacodynamic parameters and biomarkers," said Richard Miller, M.D.